Biovica announces that the study from Karolinska indicates robust clinical support for expanding future use of DiviTum to monitoring response to immunotherapy for patients with metastatic cutaneous melanoma.
ANNONS
Biovica announces that the study from Karolinska indicates robust clinical support for expanding future use of DiviTum to monitoring response to immunotherapy for patients with metastatic cutaneous melanoma.